CDK Inhibitors
Uncontrolled cellular proliferation mediated by the dysregulation of cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) is the hallmark of cancer. Agents targeting CDKs have been considered as promising therapeutic targets in cancer treatment. Although the first-generation pan-CDK inhibitors failed in clinical trials because of their adverse events and low efficacy, most recently, a new generation of selective CDK4/6 inhibitors, including Ribociclib, Abemaciclib and Palbociclib, has shown potent efficacy with tolerable safety in preclinical and clinical studies. Recent approval of Palbociclib (Ibrance®) by the U.S. Food and Drug Administration (FDA) for the treatment of ER-positive and HER2-negative breast cancer demonstrates that CDK inhibitors with high selectivity profiles can have clinical utility for therapy based on individual tumor genetics. BioVision is proud to offer >25 potent and selective CDK inhibitors including Palbociclib (PD0332991), Abemaciclib (LY-2835219), Dinaciclib, and Ribociclib for research.
